Report cover image

Growth Opportunities in Obesity Drugs and Delivery Platforms

Publisher Frost & Sullivan
Published Nov 28, 2023
SKU # MC18352228

Description

Growth Opportunities in Obesity Drugs and Delivery Platforms



The increasing disposable incomes in developing countries have contributed to a sedentary lifestyle worldwide. The advent of food delivery apps has also increased accessibility to various culinary delights. These factors have contributed mainly to obesity and other lifestyle diseases.

People with a body mass index (BMI) of more than or equal to 30 (or 27kg/m2) are classified as obese and may or may not have co-morbidities. Obesity is also known to increase the risk of several diseases, such as type 2 diabetes, cancer mortality, overall mortality, and cardiovascular disorders. It also worsens the prognosis of several diseases and other related co-morbidities.

An active lifestyle with healthy eating practices is crucial for maintaining optimal BMI. Dietary supplementation with fibers, vitamins, minerals, probiotics, and other nutrients can also help manage weight. In addition, healthcare professionals are exploring behavioral interventions for obesity management. Bariatric surgery is the gold standard for obesity treatment. However, recent therapeutic advancement has enabled the launch of oral and injectable drugs for weight loss. GLP-1-based obesity treatments are fast emerging as potent treatment options for obesity and have a favorable safety profile.

In this study, Frost & Sullivan analyzes the emerging and recently approved obesity treatment pipelines and associated advances in drug delivery technologies. We also provide insights into funding, the collaborative landscape of obesity treatments and delivery platforms, the clinical trial landscape for obesity management, and the mechanism of action of promising anti-obesity drug candidates.

Table of Contents

Strategic Imperatives
Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Obesity Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology
Growth Opportunity Analysis
Overview of Noncommunicable Diseases (NCDs)
Scope
Segmentation
Growth Drivers
Growth Restraints
Obesity Drugs: Pipeline Analysis
Overview of Approved Obesity Drugs
Game Changers for Obesity Management
Addressing the Challenges of Blockbuster Obesity Drugs
Overview of the Obesity Clinical Trial Landscape
Pipeline Analysis of Obesity Drugs
Regulatory Landscape Overview for Anti-Obesity Drugs: The United States and Europe
Major Emerging GLP-based Dual Receptor Agonists
Major Emerging GLP-based Obesity Drugs in Phase 2 and 3 Clinical Trials
Snapshot of Emerging Non-GLP Obesity Drugs
Snapshot of Emerging Non-GLP Obesity Drugs
Drug Delivery Innovations
Overview of Drug Delivery Innovations
Features of Drug Delivery Innovations
Snapshot of Emerging Drug Delivery Innovations: Injector Platforms
Snapshot of Emerging Drug Delivery Innovations: Nanomaterial Platforms
Obesity Drugs and Delivery Platforms: Acquisitions, Partnerships, and Funding
Acquisitions by Large Pharma Companies
Pharma Collaborations
Overview of the Funding Landscape for Obesity Drug Delivery
Snapshot of the Partnership Landscape for Obesity Drug Delivery
Obesity Outlook
A Multipronged Approach to Obesity Management
The Future of Drug Delivery Platforms for Obesity Management
Growth Opportunity Universe
Growth Opportunity 1: GLP-1-based Multi-agonists
Growth Opportunity 1: GLP-1-based Multi-agonists
Growth Opportunity 2: Individualized Treatment Strategy
Growth Opportunity 2: Individualized Treatment Strategy
Growth Opportunity 3: The Use of Needle-free Drug Delivery Technologies
Growth Opportunity 3: The Use of Needle-free Drug Delivery Technologies
Next Steps
Your Next Steps
Why Frost, Why Now?
Legal Disclaimer

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us